These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 17440984)

  • 21. Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia.
    Weston H; Cowell V; Grimmett K; Saal R; Jones M; Mills T; Gill D; Marlton P; Bird R; Mollee P
    Intern Med J; 2011 May; 41(5):408-15. PubMed ID: 20681956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study on the Clinical Significance of JAK2V617F Allele Burden in Philadelphia Chromosome-Negative Myeloproliferative Neoplasm.
    Chen P; Ouyang J; Liang J; Yu X; Huang B
    Clin Lab; 2016 Aug; 62(8):1477-1481. PubMed ID: 28164603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.
    Tefferi A; Lasho TL; Schwager SM; Strand JS; Elliott M; Mesa R; Li CY; Wadleigh M; Lee SJ; Gilliland DG
    Cancer; 2006 Feb; 106(3):631-5. PubMed ID: 16369984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. JAK2V617F mutation and allele burden are associated with distinct clinical and morphological subtypes in patients with essential thrombocythaemia.
    Pich A; Riera L; Beggiato E; Nicolino B; Godio L; Campisi P; Sismondi F; di Celle PF
    J Clin Pathol; 2012 Oct; 65(10):953-5. PubMed ID: 22718845
    [No Abstract]   [Full Text] [Related]  

  • 25. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.
    Arellano-Rodrigo E; Alvarez-Larrán A; Reverter JC; Colomer D; Villamor N; Bellosillo B; Cervantes F
    Am J Hematol; 2009 Feb; 84(2):102-8. PubMed ID: 19105233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
    Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
    Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients.
    Coucelo M; Caetano G; Sevivas T; Almeida Santos S; Fidalgo T; Bento C; Fortuna M; Duarte M; Menezes C; Ribeiro ML
    Int J Hematol; 2014 Jan; 99(1):32-40. PubMed ID: 24277659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of clonality assessment in JAK2V617F-negative essential thrombocythemia.
    Martínez-Avilés L; Álvarez-Larrán A; Besses C; Navarro G; Torres E; Longarón R; Angona A; Pedro C; Florensa L; Serrano S; Bellosillo B
    Ann Hematol; 2012 Oct; 91(10):1555-62. PubMed ID: 22706669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The quantitative assay and clinical significance of JAK2V617F mutation in 131 patients with chronic myeloproliferative disorders].
    Shen YM; Chao HY; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
    Zhonghua Nei Ke Za Zhi; 2009 Feb; 48(2):140-3. PubMed ID: 19549471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the "early" prepolycythemic phase of polycythemia vera and essential thrombocythemia.
    Gianelli U; Iurlo A; Vener C; Moro A; Fermo E; Bianchi P; Graziani D; Radaelli F; Coggi G; Bosari S; Deliliers GL; Zanella A
    Am J Clin Pathol; 2008 Sep; 130(3):336-42. PubMed ID: 18701405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients.
    Pardanani A; Lasho TL; Hussein K; Schwager SM; Finke CM; Pruthi RK; Tefferi A
    Mayo Clin Proc; 2008 Apr; 83(4):457-9. PubMed ID: 18380991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder.
    Pardanani A; Lasho TL; Schwager S; Finke C; Hussein K; Pruthi RK; Tefferi A
    Leukemia; 2007 Aug; 21(8):1828-9. PubMed ID: 17460706
    [No Abstract]   [Full Text] [Related]  

  • 34. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.
    Wolanskyj AP; Lasho TL; Schwager SM; McClure RF; Wadleigh M; Lee SJ; Gilliland DG; Tefferi A
    Br J Haematol; 2005 Oct; 131(2):208-13. PubMed ID: 16197451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.
    Bertozzi I; Bogoni G; Biagetti G; Duner E; Lombardi AM; Fabris F; Randi ML
    Ann Hematol; 2017 Aug; 96(8):1297-1302. PubMed ID: 28585070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The clinical implication of JAK2 mutation expression in patients with myeloproliferative disorders].
    Fei HR; Zhang R; Chen SN; Pan JL; Cen JN; Xue YQ
    Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):271-3. PubMed ID: 17637260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Expression of JAK2V617F and MPLW515L/K mutation in 30 suspected cases of early myeloproliferative disorders].
    Fan Z; Zhang R; Shen YM; Fei HR; Zhu ZL; Cen JN
    Zhonghua Xue Ye Xue Za Zhi; 2008 Sep; 29(9):611-4. PubMed ID: 19175989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between JAK2V617F mutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms.
    Hu L; Pu L; Ding Y; Li M; Cabanero M; Xie J; Zhou D; Yang D; Zhang C; Wang H; Zhai Z; Ru X; Li J; Xiong S
    Hematology; 2017 Jul; 22(6):354-360. PubMed ID: 27976991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Quantitative analysis for JAK2 mutation in 98 patients with essential thrombocythemia and its clinical significance].
    Chao HY; Shen YM; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):665-9. PubMed ID: 19549384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis.
    Martínez-Trillos A; Maffioli M; Colomer D; Alvarez-Larrán A; Pereira A; Angona A; Bellosillo B; Cervantes F
    Ann Hematol; 2014 May; 93(5):797-802. PubMed ID: 24337516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.